Avastin + Gemcitabine + Oxaliplatin + Pegaspargase + Dexamethasone

Phase 2UNKNOWN

1 views this week 0 watching💤 Quiet

Interest: 31/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Extranodal NK/T-cell Lymphoma, Nasal Type

Conditions

Extranodal NK/T-cell Lymphoma, Nasal Type

Trial Timeline

Aug 1, 2013 → Aug 1, 2020

NCT ID

NCT01921790

About Avastin + Gemcitabine + Oxaliplatin + Pegaspargase + Dexamethasone

Avastin + Gemcitabine + Oxaliplatin + Pegaspargase + Dexamethasone is a phase 2 stage product being developed by Eli Lilly for Extranodal NK/T-cell Lymphoma, Nasal Type. The current trial status is unknown. This product is registered under clinical trial identifier NCT01921790. Target conditions include Extranodal NK/T-cell Lymphoma, Nasal Type.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01921790	Phase 2	UNKNOWN	Aug 1, 2013	Aug 1, 2020	Extranodal NK/T-cell Lymphoma, Nasal Type

Competing Products

8 competing products in Extranodal NK/T-cell Lymphoma, Nasal Type

See all competitors

Product	Company	Stage	Hype Score
High dose of methotrexate + Gemcitabine + Pegaspargase + Dexamethasone	Eli Lilly	Phase 2	31
Camrelizumab	Jiangsu Hengrui Medicine	Phase 2	31
SHR-1210	Jiangsu Hengrui Medicine	Phase 2	31
avelumab	Merck	Phase 2	31
Pembrolizumab	Merck	Phase 2	42
PI3K inhibitor BKM120 + rituximab	Novartis	Phase 1	29
carfilzomib	Amgen	Phase 1	29
IBI318(Recombinant human anti-PD1/PD-L1 bispecific antibody)	Innovent Biologics	Phase 1/2	24